ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Active, not recruiting · Phase 3 · NCT05949684
Conditions: Myelodysplastic Syndromes
At a glance
- Research payments reported, 2025
- $515,926
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 402
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Luspatercept (biological), Epoetin Alfa (biological)
- Dates
- Started 2023-10-24; completion 2031-05-30
- Results posted
- Not yet
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
From ClinicalTrials.gov, last updated 2026-06-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $515,926 in research payments for this study in 2025 (15 payments).
Products named: Reblozyl
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Wanxing Chai-ho, M.D. Hematology & Oncology · Los Angeles, CA
- Gigi Q. Chen, M.D. Hematology & Oncology · Pleasant Hill, CA
- Devendra Kc, MD Medical Oncology · Hartford, CT
- Amer Zeidan Hematology & Oncology · New Haven, CT
- Gustavo A. Fonseca, MD Medical Oncology · Lecanto, FL
- Rami S. Komrokji, M.D. Hematology · Tampa, FL
- Maxim Norkin, MD, PHD Hematology · Jacksonville, FL
- Yasmin Abaza, M.D. Hematology & Oncology · Chicago, IL
- Marshall P. Stagg II, MD Hematology & Oncology · Baton Rouge, LA
- Yan Ji, M.D, PH.D. Hematology & Oncology · Saint Paul, MN
- Syed Y. Zafar, MD Hematology & Oncology · Durham, NC
- Uma M. Borate, MD Hematology · Columbus, OH
- Wahid T. Hanna, MD Hematology · Knoxville, TN
- Guillermo Garcia-manero, M.D. Hematology & Oncology · Houston, TX
- Amanda L. Gillespie-twardy, M.D. Hematology & Oncology · Roanoke, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Smilow Hospital Cancer Center at Yale New Haven $111,742
- University Health System, Inc, TN $69,174
- Blue Ridge Cancer Care $47,625
- Hartford Hospital, CT $44,567
- Florida Cancer Specialists - South $42,568
- Ut MD Anderson Cancer Center $41,005
- Arthur G James Cancer Hospital $35,924
- Baptist Health Medical Center - Jacksonville, FL $34,644
- Florida Cancer Specialists - North $19,920
- Metro Minnesota Community Oncology Research Consortium $15,099
- Northwestern Memorial Hospital Galter PAvilion $12,641
- UCLA Hematology/oncology - Westwood (building 200 Suite 120) $12,188
- Our Lady of the Lake Rmc $12,188
- John Muir Health Cancer Medical Group $10,642
- Moffitt Cancer Center $5,997
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.